<DOC>
	<DOCNO>NCT01934192</DOCNO>
	<brief_summary>This multi-center , parallel group , placebo-controlled active-compared , randomize study assess ability GSK962040 enhance delivery enteral feed critically ill subject predispose develop feed intolerance ( e.g. , percentage goal volume ) ; enhance gastric empty population ; provide preliminary evidence drug 's effect outcomes therapy ( length stay Intensive Care Unit [ ICU ] , time ventilator , ICU acquire infection , 60-day mortality ) . Other aims evaluation GSK962040 safety , tolerability pharmacokinetics upon repeat dose critically ill population . After meet eligibility criterion , male female subject randomize either receive GSK962040 ( 50 milligram [ mg ] ) daily ( OD ) via naso-gastric ( NG ) orogastric ( OG ) feed tube ( oral solution ) , placebo route . If subject develop intolerance enteral feeding point Dose 5 study medication ( inclusive ) , study treatment switch originally receive GSK962040 receive metoclopramide ( 10 mg , intravenous [ iv ] , every 6 hour ) subject originally randomize receive placebo receive GSK962040 ( 50 mg , via NG , OD ) . Additionally , subject develop intolerance prior treatment , randomize receive either GSK962040 ( 50 mg , via NG , OD ) metoclopramide ( 10 mg , iv , every 6 hour ) . The study consist screening/baseline assessment , treatment period ( 7 day duration ) , 4-day post treatment safety follow-up assessment . The duration subject 's participation study screen follow-up safety assessment approximately 2 week . In addition , mortality assess 60 day admission ICU .</brief_summary>
	<brief_title>Nutritional Adequacy Therapeutic Enhancement Critically Ill . The NUTRIATE Study</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<criteria>Age &amp; Gender : Male female 18 85 year age inclusive , time obtain informed consent . First admit participate ICU within previous 48 hour . Intubated invasively mechanically ventilate Indicated receive early EN already receive EN ( subject must EN prior receive study treatment ) Have least one follow Clinical evidence cardiovascular dysfunction define need vasopressor agent ( e.g . norepinephrine , epinephrine , vasopressin ) , &gt; 5 microgram/kg/min dopamine , &gt; /= 50 microgram/min phenylephrine ) great equal 2 hour ; Polytrauma injury severity score ( ISS ) &gt; =15 point Acute traumatic nontraumatic brain injury Glasgow Coma Scale ( GCS ) &lt; =12 , prior initiation sedation . Subjects expect ICU alive least 48 hrs point screening . Subjects acute hepatitis ( e.g . acute hepatitis B C ) severe chronic liver disease ( e.g . Child Pugh class C cirrhosis ) exclude Liver function test : If Alanine aminotransferase ( ALT ) &gt; =8x upper limit normal ( ULN ) ; OR If ALT &gt; 58x ULN bilirubin &gt; 2 &lt; =3 ULN bilirubin &gt; 3x ULN ( Include bilirubin &lt; 1.5xULN ) ; OR If ALT &lt; =5xULN Bilirubin &gt; 3xULN ( Include ALT &lt; =3xULN Bilirubin &gt; 2 &lt; =3xULN ) Subjects receive gastric prokinetic agent previous 12 hour ( e.g. , erythromycin , azithromycin , metoclopramide , domperidone ) . QT duration correct heart rate ( QTc ) &gt; 480 ms. QTcF recommend correction factor site . If QT duration correct heart rate Fridericia 's formula ( QTcF ) possible obtain calculate , QT duration correct heart rate Bazett 's formula ( QTcB ) machine manual read , may obtain consultation medical monitor . The QT correction formula use determine inclusion discontinuation throughout study . Use strong Cyp3A4 inhibitor Subjects require renal replacement therapy estimate glomerular filtration rate ( GFR ) &lt; 30 mL/min byCockroftGault calculation ) . Subjects history undergone major esophageal gastric surgery admission ( major low abdominal surgery result exclusion unless carry contraindication enteral feeding ) . Subjects absolute contraindication enteral nutrition e.g . subject ongoing bowel obstruction perforation . Subject gastric pacemaker Pregnant lactating female History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Concurrent enrollment interventional study involve novel ( i.e.unapproved experimental ) chemical biopharmaceutical entity . Previous randomization study Subjects reason admission ICU overdose ( deliberate accidental ; medicinal product ) . Exclusion rerandomization : Subjects untreated pheochromocytoma . Subjects past history seizure disorder ( e.g. , epilepsy ) currently receive antiepileptic treatment seizure disorder , ongoing refractory , sustain seizure disorder ( prophylactic use head injury/isolated new seizure maintain antiseizure med ICU acceptable ) . Subjects take drug likely cause extrapyramidal reaction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tolerability</keyword>
	<keyword>camicinal</keyword>
	<keyword>single dose</keyword>
	<keyword>acetaminophen</keyword>
	<keyword>gastric empty</keyword>
	<keyword>critically ill</keyword>
	<keyword>GSK962040</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>gut motility</keyword>
</DOC>